MBX Biosciences Statistics

Total Valuation

MBX Biosciences has a market cap or net worth of $246.67 million. The enterprise value is -$15.31 million.

Market Cap	246.67M
Enterprise Value	-15.31M

Important Dates

The next estimated earnings date is Friday, May 16, 2025, before market open.

Earnings Date	May 16, 2025
Ex-Dividend Date	n/a

Share Statistics

MBX Biosciences has 33.42 million shares outstanding. The number of shares has increased by 944.70% in one year.

Current Share Class	33.42M
Shares Outstanding	33.42M
Shares Change (YoY)	+944.70%
Shares Change (QoQ)	+412.50%
Owned by Insiders (%)	3.16%
Owned by Institutions (%)	43.16%
Float	13.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.96
P/TBV Ratio	0.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 24.19, with a Debt / Equity ratio of 0.00.

Current Ratio	24.19
Quick Ratio	23.78
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -36.71% and return on invested capital (ROIC) is -25.23%.

Return on Equity (ROE)	-36.71%
Return on Assets (ROA)	-24.17%
Return on Invested Capital (ROIC)	-25.23%
Return on Capital Employed (ROCE)	-26.48%
Revenue Per Employee	n/a
Profits Per Employee	-$1.44M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	8.95
200-Day Moving Average	n/a
Relative Strength Index (RSI)	46.55
Average Volume (20 Days)	341,252

Short Selling Information

The latest short interest is 5.08 million, so 15.20% of the outstanding shares have been sold short.

Short Interest	5.08M
Short Previous Month	4.57M
Short % of Shares Out	15.20%
Short % of Float	37.32%
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-68.19M
Pretax Income	-47.20M
Net Income	-61.92M
EBITDA	-67.95M
EBIT	-68.19M
Earnings Per Share (EPS)	-$5.82

Full Income Statement

Balance Sheet

The company has $262.15 million in cash and $171,000 in debt, giving a net cash position of $261.98 million or $7.84 per share.

Cash & Cash Equivalents	262.15M
Total Debt	171,000
Net Cash	261.98M
Net Cash Per Share	$7.84
Equity (Book Value)	257.44M
Book Value Per Share	7.70
Working Capital	256.24M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$54.68 million and capital expenditures -$874,000, giving a free cash flow of -$55.56 million.

Operating Cash Flow	-54.68M
Capital Expenditures	-874,000
Free Cash Flow	-55.56M
FCF Per Share	-$1.66

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MBX Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-944.70%
Shareholder Yield	-944.70%
Earnings Yield	-25.10%
FCF Yield	-22.52%

Analyst Forecast

The average price target for MBX Biosciences is $37.40, which is 406.78% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$37.40
Price Target Difference	406.78%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2